SciSparc (SPRC) announced that as part of its ongoing collaboration with Clearmind Medicine (CMND), Clearmind has submitted a patent application under the international Patent Cooperation Treaty. The patent application refers to the novel proprietary composition of Clearmind’s MEAI compound with palmitoylethanolamide, the active ingredient of SciSparc’s proprietary CannAmide, for preventing and/or treating depression. This application was previously filed as a provisional patent application with the United States Patent and Trademark Office.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRC:
- SciSparc announces MitoCareX Bio virtually screened molecules using platform
- SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
- SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
- SciSparc granted patent for core-technology
- SciSparc doses first patient in Autism Spectrum Disorder trial
